Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics, Inc. (FDMT)
:FDMT
FDMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.24 - $17.41
Previous CloseN/A
Volume165.32K
Average Volume (3M)1.61M
Market Cap
$280.26M
Enterprise Value-$117.53M
Total Cash (Recent Filing)$321.44M
Total Debt (Recent Filing)$23.85M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 05, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,324,642
10 Day Avg. Volume4,125,809
30 Day Avg. Volume1,608,850
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.42
Enterprise Value/Revenue-5.11K
Enterprise Value/Gross Profit-72.68
Enterprise Value/Ebitda0.58
Forecast
1Y Price Target
$30.83Price Target Upside409.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEnrollment for 4FRONT-1 has exceeded projections, indicating increased interest in 4D-150.
Financial StabilityFDMT reiterated its expectations for its cash balance to support operations into 2028, highlighting financial stability.
Safety ProfileThe 4D-150 continues to have a favorable safety profile with no signs of intraocular inflammation observed through week 60 in the cohort of 22 DME patients.
Bears Say
Developmental RisksRisks include failure of developmental candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.
Leadership ChangesThe resignation of CFO/CBO Uneek Mehra might indicate potential leadership changes or challenges within the company.
Workforce ReductionFDMT announced a ~25% workforce reduction of current/planned roles across early-stage R&D and support functions.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics, Inc.’s price range in the past 12 months?
4D Molecular Therapeutics, Inc. lowest stock price was $2.23 and its highest was $17.41 in the past 12 months.
What is 4D Molecular Therapeutics, Inc.’s market cap?
4D Molecular Therapeutics, Inc.’s market cap is $280.26M.
When is 4D Molecular Therapeutics, Inc.’s upcoming earnings report date?
4D Molecular Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.
How were 4D Molecular Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is 4D Molecular Therapeutics, Inc. overvalued?
According to Wall Street analysts 4D Molecular Therapeutics, Inc.’s price is currently Undervalued.
Does 4D Molecular Therapeutics, Inc. pay dividends?
4D Molecular Therapeutics, Inc. does not currently pay dividends.
What is 4D Molecular Therapeutics, Inc.’s EPS estimate?
4D Molecular Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4D Molecular Therapeutics, Inc. have?
4D Molecular Therapeutics, Inc. has 46,324,642 shares outstanding.
What happened to 4D Molecular Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 4D Molecular Therapeutics, Inc.?
Currently, no hedge funds are holding shares in FDMT
4D Molecular Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.83 (409.59% Upside)
$30.83 (409.59% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.8%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.03%
12-Months-Change
Fundamentals
Return on Equity
-32.97%
Trailing 12-Months
Asset Growth
-18.12%
Trailing 12-Months
Company Description
4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$30.83
▲(409.59% Upside)
Technical Analysis
Ownership Overview
12.57% Insiders
15.06% Mutual Funds
1.83% Other Institutional Investors
60.57% Public Companies and
Individual Investors